Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
Completed
GlaxoSmithKline
Phase 1
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as
compared to placebo and moxifloxacin. This a four period crossover design with each period
lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men
Completed
GlaxoSmithKline
Phase 1
This study is being conducted to provide initial safety, tolerability, PK and PD data that
will allow further studies with darapladib in Japanese patients
Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-
Completed
GlaxoSmithKline
Phase 1
This study is being conducted to provide safety, tolerability, PK and PD data in repeat
dosing that will allow further studies with darapladib in Japanese patients
A Study With Darapladib to Collect Tolerability Information
Completed
GlaxoSmithKline
Phase 1
Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and
the remaining 9 days of dosing will occur at home. Subjects will record any adverse events
throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days
after the last dose of darapladib for a follow-up visit. The total study duration for each
subject including the screening, treatment and follow-up periods will be approximately 4
weeks.
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
Completed
GlaxoSmithKline
Phase 2
The primary objective of this study is to examine the effects of SB-480848 on plasma
lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a
4-week treatment with SB-480848.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
